Synaptogenix Inc (SNPX): My updated (in bold) notes of Susanne Wi...

Reply Private New

Replies (4) Next 10 Prev Next

Send PM Follow Ignore

Followers	7
Posts	410
Boards Moderated	0
Alias Born	06/04/2014

SF Wolf

Re: None

Monday, 02/06/2017 12:15:59 PM

Monday, February 06, 2017 12:15:59 PM

My updated (in bold) notes of Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, presentation at the Noble Financial Capital on 1/30/17:

Minute 8:25 "we are seeing remarkable results in reversal of Alzheimer's Disease"

Minute 10:41 "with this license we are able to synthesize Bryostatin in larger commercial quantities"

Minute 17:58 "we have compassionate use protocol results in Alzheimer patients that shows significant improvement in cognition and daily living..."

Minute 18:25: “we have Phase 2a completed which was a smaller Phase 2. We achieved our primary safety endpoint, we saw targeted engagement and we saw some limited cognitive enhancement in a short period of time.

Minute 26:42: “we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.

Top line results in April.

http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d